PHILA: Pyrotinib-Based Dual Anti-HER2 Regimen Extended Survival in Metastatic Breast Cancer - Oncology Nurse Advisor Investigators delivered updated results from the phase 3 PHILA trial evaluating the pyrotinib or placebo plus trastuzumab and docetaxel in patients with untreated HER2+metastatic breast cancer.

Pyrotinib plus trastuzumab and docetaxel outperformed trastuzumab and docetaxel alone as an initial treatment for HER2-positive metastatic #breastcancer. Published in @bmj.com and @cancertherapyadv.bsky.social.

https://bit.ly/47TBedD

#bcsm

Dr Kalinsky on the Role of Tumor Boards in Metastatic Breast Cancer Management | OncLive Kevin Kalinsky, MD, MS, FASCO, notes the advantages of collaborating with multidisciplinary tumor boards when managing metastatic breast cancer.

WATCH: @kalinskykevin.bsky.social, of @winshipcancer.emory.edu, notes the advantages of collaborating with multidisciplinary tumor boards when managing metastatic breast cancer. #MBCC26 #bcsm #oncology
www.onclive.com/view/dr-kali...

The use of taxane-based chemotherapy was associated with an increased risk for #neuropathy and balance issues among #breastcancer survivors who were 65 years or older at the time of therapy. Published in @ascocancer.bsky.social journal JCO Oncology Practice.

https://bit.ly/4t3AQl0

#bcsm

Dr Diab on the Role of the BCI for Optimizing Endocrine Therapy Use in Breast Cancer | OncLive Sami Diab, MD, discusses the use of genomic assays for determining whether extended adjuvant therapy is needed for patients with breast cancer.

WATCH 👀: Sami Diab, MD, discusses the use of genomic assays for determining whether extended adjuvant therapy is needed for patients with breast cancer.

📷 See the whole video here: www.onclive.com/view/dr-diab...

#bcsm #oncology

Want to learn more about the presentations from #MBCC26? #bcsm experts share takeaways and lingering questions from the meeting.

⭐ Sign up to read: www.onclive.com/view/multidi...

@kalinskykevin.bsky.social @winshipcancer.emory.edu @mskcancercenter.bsky.social @fredhutch.org #bcsm #oncology

🎙️The first episode of the Breast Cancer Briefing podcast is LIVE! Sara Nunnery, MD, MSCI, & Kelly E. McCann, MD, PhD, discussed the HER2+ breast cancer treatment paradigm. #bcsm #oncology

WATCH the video podcast on our site, or LISTEN where you get your podcasts ➡️ www.onclive.com/view/t-dxd-t...

Dr Diab on Using the BCI for Recurrence Risk Assessment in HR+ Breast Cancer | OncLive Sami Diab, MD, discusses facets of individualized risk assessment for premenopausal patients with early-stage HR-positive, node-negative breast cancer.

WATCH 👀: Sami Diab, MD, discusses facets of individualized risk assessment for premenopausal patients with early-stage HR-positive, node-negative breast cancer.

📷 See the whole video here: www.onclive.com/view/dr-diab...

#bcsm #oncology

Dr Diab on the Value of the Breast Cancer Index for Assessing Disease Recurrence Risk | OncLive Sami Diab, MD, discusses the value of the Breast Cancer Index for identifying disease recurrence risk in breast cancer after adjuvant endocrine therapy.

WATCH 👀: Sami Diab, MD, discusses the value of the Breast Cancer Index for identifying disease recurrence risk in breast cancer after adjuvant endocrine therapy.

📷 See the whole video here: www.onclive.com/view/dr-diab...

#bcsm #oncology

A pleasure having Professor Steffi Oesterreich @upmchillmancc.bsky.social @upmc.com @mageewomens.bsky.social visit us at @wchospital.bsky.social today and discussing #research collaborations in #lobular #breastcancer #bcsm
@lobularbca.bsky.social

PHILA: Pyrotinib-Based Dual Anti-HER2 Regimen Extended Survival in Metastatic Breast Cancer Investigators delivered updated results from the phase 3 PHILA trial evaluating the pyrotinib or placebo plus trastuzumab and docetaxel in patients with untreated HER2+metastatic breast cancer.

Pyrotinib plus trastuzumab and docetaxel outperformed trastuzumab and docetaxel alone as an initial treatment for HER2-positive metastatic #breastcancer. Published in the @bmj.com.

https://bit.ly/40SqeJJ

#bcsm

WATCH 👀: Marla Lipsyc-Sharf, MD, of @uclahealth.org, discusses the evolution of ctDNA testing in breast cancer management. #bcsm #oncology

📷 Check out the full interview for more breast cancer testing insights from Dr Lipsyc-Sharf! www.onclive.com/shorts/explo...

Dr Lipsyc-Sharf on the Use of the Signatera Genome Assay in Breast Cancer Management | OncLive Marla D. Lipsyc-Sharf, MD, highlights the clinical evolution of the Signatera Genome test for residual disease surveillance in patients with breast cancer.

WATCH 👀: Marla D. Lipsyc-Sharf, MD of @uclahealth.org, highlights the clinical evolution of the Signatera Genome test for residual disease surveillance in patients with breast cancer.

📷 See the whole video here: www.onclive.com/view/dr-lips...

#bcsm #oncology

Dr Diab on the Clinical Relevance of the Breast Cancer Index in HR+ Early-Stage Disease | OncLive Sami Diab, MD, highlights the use of the BCI for guiding adjuvant hormonal therapy decision-making in patients with early-stage, HR-positive breast cancer.

WATCH 👀: Sami Diab, MD, highlights the use of the BCI for guiding adjuvant hormone therapy decisions in early-stage, HR+ breast cancer.

📷 See the whole video here 📷: www.onclive.com/view/dr-diab...

#bcsm #oncology

WATCH: Sami Diab, MD, emphasizes the importance of considering different patient priorities in cancer care.

See our site for more breast cancer management insights! #bcsm #oncology

www.onclive.com/clinical/bre...

Just released a couple of new episodes of my podcast - Never knew I wanted to be a breast cancer survivor #bcsm bcbecky.com/wp-admin

Combination Treatment Benefits Patients With Advanced Breast Cancer That Has Spread to Brain | OncLive Tucatinib and trastuzumab, plus capecitabine, may improve symptoms and extend survival in some breast cancer patients with leptomeningeal metastasis.

A study from @danafarber.bsky.social demonstrated that tucatinib and trastuzumab, plus capecitabine, may improve symptoms and extend survival in some breast cancer patients with leptomeningeal metastasis. #oncology #bcsm
Read more here: www.onclive.com/view/combina...

Have you checked out our newest episode? In our "Report Back from SABCS" Dr. Bora Lim shares some of the notable highlights you need to stay informed & educated with what's new in #MetastaticBreastCancer treatment.
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#BCSM #CanSky

Online patient materials for #AI in #mammography exceed recommended 6th-grade readability levels. Analysis shows most content requires a college-level education.

Read the review: ➡️ https://bit.ly/4uBkKRf

#BCSM #MedEd #HealthLiteracy

Sacituzumab govitecan–based regimens now hold category 1 preferred regimen recommendations for the first-line treatment of metastatic triple-negative breast cancer in the updated NCCN Guidelines #bcsm #oncology www.onclive.com/view/updated...

Dr. Lim from @utmdanderson.bsky.social discusses targeted therapy, ADC's moving to first line, emerging treatments for TNBC and more.
🎧 Listen (all channels) or 🔗 buff.ly/rOQzgg5
#MBC #SABCS #ClinicalTrials #BCSM #CanSky #podcast

WATCH: Hung Khong, MD, previews future directions for investigating RSK inhibition in breast cancer. See our additional coverage of this research for more insights from Dr Khong! #bcsm #oncology
www.onclive.com/view/rsk-inh...

GLSI-100 Yields Low Recurrence Rate in High-Risk HER2+ Breast Cancer After Perioperative Therapy | OncLive Patients with HLA-A*02–negative, HER2-positive early breast cancer experienced a recurrence rate of less than 1% when treated with GLSI-100.GLSI-100

According to data from the ongoing phase 3 FLAMINGO-01 trial, patients with HLA-A*02–negative, HER2-positive early breast cancer experienced a recurrence rate of less than 1% when treated with GLSI-100. #oncology #bcsm #HER2breastcancer
Read more here: www.onclive.com/view/glsi-10...

High caliber study &
there’s a lot to unpack here, eg
“Patients who received CAM only had the highest mortality…followed by untreated patients”
#bcsm
#oncosky
#cancersky

For patients with metastatic #breastcancer and their partners, a couples-based sexual quality-of-life intervention called Adapted Intimacy Enhancement has shown potential benefits. From @americancancersoc.bsky.social.

https://bit.ly/3P6ciZW

#bcsm

Father of 3 ‘Shocked’ by Rare Breast Cancer Diagnosis on 53rd Birthday, Says Regular Testing ‘Saved My Life’ (Exclusive) After discovering he carried the BRCA2 gene in 2013, one man began getting yearly mammograms. Twelve years later, he was still “shocked” to learn he had breast cancer and is now sharing his story to r...

In 2013, following a strong #familyhistory of #breastcancer, Jacob Johnson learned he was #BRCA2 +. Over a decade later, at the age of 53, the father of 3 was diagnosed with a rare & aggressive form of cancer in his right breast.

#bcsm #hereditarycancer #menshealth #genetics #patientexperience

Dr Moslehi on the Importance of Multidisciplinary Collaboration in Cancer Care | OncLive Javid Moslehi, MD, discusses the role of the cardiologist in the setting of breast cancer management to facilitate optimal cancer management.

WATCH 👀: Javid Moslehi, MD, of @ucsfhealth.bsky.social, discusses the role of the cardiologist in the setting of breast cancer management to facilitate optimal cancer management.

See the whole video here 📷: www.onclive.com/view/dr-mosl...

#bcsm #oncology

Dr Esserman on the Potential Role for Risk-Based Breast Cancer Screening | OncLive Laura J. Esserman, MD, MBA, discusses the potential utility of risk-based screening for breast cancer.

Could risk-based approaches improve breast cancer screening strategies? Laura J. Esserman, MD, MBA, of @ucsfcancer.bsky.social, explains the potential utility and benefits of this method #bcsm #oncology

Watch now: www.onclive.com/view/dr-esse...

LinkedIn This link will take you to a page that’s not on LinkedIn

Those interested in #Socialmedia in health care, check our this project Previvorship www.previvorship.org) report on Social Media for Carriers of Hereditary Syndromes lnkd.in/eds-kMDm #gyncsm #lynchsyndrome #BRCA #bcsm

Join @TriageCancer on 3/24 for a FREE webinar on navigating common #HealthInsurance hurdles. The session will cover prior authorizations, co-pay accumulators, step therapy, denials, & more. + FREE CE for professionals.
Register today: buff.ly/InUI1SG
#CancerRights #TriageTalks #BCSM #CanSky

RadOnc and Recon: Surveying the Landscape of Radiation and Reconstruction in Breast Cancer

This 📄 reviews the evidence regarding #bcsm reconstruction and #radiation, and discuss the decision-making process for patients with #breastcancer and their providers.

@mdanderson.bsky.social @astro-org.bsky.social

📌 rdcu.be/e7LYp